Receptos Announces Oral Podium Presentation at Annual Meeting of European Crohn's and Colitis Organization (ECCO)
19 February 2015 - 12:00AM
- Detailed Results of Positive Phase 2 Trial of
RPC1063 in Ulcerative Colitis to be Presented on February 21, 2015
-
- Company to Host Investor Call and Webcast on
February 23, 2015 -
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that data from TOUCHSTONE, the
Company's Phase 2 trial of RPC1063 in ulcerative colitis (UC), will
be reviewed in an oral podium presentation at the ECCO conference
on February 21, 2015 in Barcelona, Spain. ECCO is the largest
annual meeting of the European Crohn's and Colitis Organization.
The data will be presented by Dr. William Sandborn, Principal
Investigator of the trial, Chief of the Division of
Gastroenterology and Director of the UC San Diego IBD
Center. Details are as follows:
Saturday, February 21, 2015, 9:40 a.m. Session: New
Therapies and Strategies Plenary Hall, Ground level
CCIB, Plaça de Willy Brandt, 11-14, 08019 Barcelona Abstract
Number: A-1273
In addition, Receptos will host a teleconference and webcast to
discuss the results in further detail on Monday, February 23 at
8:30 a.m. ET. The live call may be accessed by phone by
calling (866) 757-6808 (domestic) or (760) 536-5211
(international), participant code 90131024. The webcast can be
accessed live on the Investor Relations section of the Receptos
website at www.receptos.com and will be archived for 14 days
following the call. A replay of the call will be available by
phone by calling (855) 859-2056, participant code 90131024.
About RPC1063
RPC1063 is a novel, oral, once daily, selective sphingosine
1-phosphate 1 and 5 receptor modulator in development for
autoimmune indications including relapsing multiple sclerosis (RMS)
and ulcerative colitis (UC). In a Phase 2 trial in patients
with RMS, RPC1063 achieved the primary endpoint of reduction in MRI
brain lesion activity as well as secondary endpoints measuring
effects on other MRI parameters. The overall safety profile of
RPC1063 was consistent with the results of prior trials and
continues to demonstrate differentiation against other oral agents
for treatment of RMS. Receptos is now conducting a Phase 3
clinical development program comprised of two trials: RADIANCE
and SUNBEAM, both of which are randomized, double-blind studies
designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon
beta-1a (Avonex®) in patients with RMS.
RPC1063 is also being studied in inflammatory bowel disease
(IBD). The TOUCHSTONE Phase 2 trial of RPC1063 in UC met its
primary endpoint and all secondary endpoints with statistical
significance in patients on the 1 mg dose of RPC1063 in the 8-week
induction period. The overall safety and tolerability profile
of RPC1063 was consistent with the results of the RADIANCE Phase 2
trial in RMS, and continues to support the potential for orally
administered RPC1063 to significantly improve the treatment
paradigm for UC patients. The maintenance period of the TOUCHSTONE
trial is currently ongoing. Receptos plans to initiate a Phase
3 program in UC and a Phase 2 program in Crohn's disease in
2015.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, RPC1063, is a sphingosine
1-phosphate 1 and 5 receptor small molecule modulator in
development for immune indications including RMS and
IBD. Patents supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2023 to Jul 2024